Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles

Lababidi, Nashrawan; Montefusco-Pereira, Carlos Victor; Carvalho-Wodarz, Cristiane de Souza; Lehr, Claus‐Michael; Schneider, Marc

doi:10.1016/j.ejpb.2020.10.010

Cited by 32 publications

(13 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,6,[9][10][11][12][13][14][15] There are several techniques that are used for the preparation of PLGA particles including single and double emulsion solvent evaporation (ESE), nanoprecipitation, spray-drying, microfluidics, and hydrogel templating. 2,[16][17][18][19] These techniques enable the synthesis of a wide range of PLGA nano-and sub-micron sized particles. The ideal size and polydispersity of particles vary according to the application.…”

Section: Introductionmentioning

confidence: 99%

Evaluating the effect of synthesis, isolation, and characterisation variables on reported particle size and dispersity of drug loaded PLGA nanoparticles

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluating the effect of synthesis, isolation, and characterisation variables on reported particle size and dispersity of drug loaded PLGA nanoparticles

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Powder deposited at each NGI stage was extracted, rinsed with methanol, and centrifuged for 15 min at 5000 rpm(Centrifuge 5418R Eppendorf, USA), the supernatant was collected and subjected to HPLC analysis. Aerodynamic parameters including emitted dose (ED), fine particle fraction (FPF), mass median aerodynamic diameter (MMAD), and geometric standard deviation (GSD) were calculated ( Lababidi et al., 2020 ; Singh et al., 2015b ) as follows:

…”

Section: Methodsmentioning

confidence: 99%

Inhalation potential of N-Acetylcysteine loaded PLGA nanoparticles for the management of tuberculosis: In vitro lung deposition and efficacy studies

Puri

Chaudhary

Singh

et al. 2022

Current Research in Pharmacology and Drug Discovery

View full text Add to dashboard Cite

Several studies have stated that mucus is a critical hurdle for drug delivery to the mucosal tissues. As a result, Polymeric nanoparticles that can overcome mucus barriers are gaining popularity for controlled drug delivery into intra-macrophages to attain high intracellular drug concentration. The present study was aimed to fabricate inhalable N-acetylcysteine (NAC) modified PLGA mucus penetrating particles using the double emulsion method (w/o/w) for target delivery to alveolar macrophages and minimize the dose-related adverse effects, efficiently encapsulate hydrophilic drug, sustain the release profile and prolong the retention time for the management of tuberculosis. Among the numerous formulations, the drug/polymer ratio of 1:10 with 0.50% PVA concentration and sonication time for 2 min s was chosen for further research. The formulated nanoparticles had a mean particle size of 307.50 ± 9.54 nm, PDI was 0.136 ± 0.02, zeta potential about −11.3 ± 0.4 mV, decent entrapment efficiency (55.46 ± 2.40%), drug loading (9.05 ± 0.22%), and excellent flowability. FTIR confirmed that NAC and PLGA were compatible with each other. SEM graphs elucidated that the nanoparticles were spherically shaped with a slightly rough surface whereas TEM analysis ensured the nanometer size nanoparticles and coating of lipid over NPs surface. PXRD spectrum concluded the transformation of the drug from crystalline to amorphous state in the formulation. In vitro release pattern was biphasic started with burst release (64.67 ± 1.53% within 12hrs) followed by sustained release over 48hrs thus enabling the prolonged replenishing of NAC. In vitro lung deposition study pronounced that coated NAC-PLGA-MPPs showed favorable results in terms of emitted dose (86.67 ± 2.52%), MMAD value (2.57 ± 0.12 μm), GSD value (1.55 ± 0.11 μm), and FPF of 62.67 ± 2.08% for the deposition and targeting the lungs. Finally, in vitro efficacy studies demonstrated that NAC-PLGA-MPPs presented more prominent antibacterial activity against MTB H37Rv strain as compared to NAC. Hence, PLGA based particles could be a better strategy to deliver the NAC for lung targeting.

show abstract

“…This natural compound is highly lipophilic and photo sensible, unstable in acidic and basic conditions, and rapidly metabolized and eliminated from the organism. The development of curcumin nanoparticles has been extensively reported [ 159 , 160 , 161 , 162 , 163 ] and the best results in terms of curcumin drug loading, stability, and solubility were reported by Gupta and co-workers through encapsulation in solid–lipid nanoconstructs [ 164 ].…”

Section: The Pharmacokinetics (Pk) and Pharmacodynamics (Pd) Properti...mentioning

confidence: 99%

The Promise of Nanotechnology in Personalized Medicine

Alghamdi

Fallica

Virzì

et al. 2022

JPM

View full text Add to dashboard Cite

Both personalized medicine and nanomedicine are new to medical practice. Nanomedicine is an application of the advances of nanotechnology in medicine and is being integrated into diagnostic and therapeutic tools to manage an array of medical conditions. On the other hand, personalized medicine, which is also referred to as precision medicine, is a novel concept that aims to individualize/customize therapeutic management based on the personal attributes of the patient to overcome blanket treatment that is only efficient in a subset of patients, leaving others with either ineffective treatment or treatment that results in significant toxicity. Novel nanomedicines have been employed in the treatment of several diseases, which can be adapted to each patient-specific case according to their genetic profiles. In this review, we discuss both areas and the intersection between the two emerging scientific domains. The review focuses on the current situation in personalized medicine, the advantages that can be offered by nanomedicine to personalized medicine, and the application of nanoconstructs in the diagnosis of genetic variability that can identify the right drug for the right patient. Finally, we touch upon the challenges in both fields towards the translation of nano-personalized medicine.

show abstract

Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles

Cited by 32 publications

References 48 publications

Evaluating the effect of synthesis, isolation, and characterisation variables on reported particle size and dispersity of drug loaded PLGA nanoparticles

Evaluating the effect of synthesis, isolation, and characterisation variables on reported particle size and dispersity of drug loaded PLGA nanoparticles

Inhalation potential of N-Acetylcysteine loaded PLGA nanoparticles for the management of tuberculosis: In vitro lung deposition and efficacy studies

The Promise of Nanotechnology in Personalized Medicine

Contact Info

Product

Resources

About